Cantor Fitzgerald Comments on Tourmaline Bio FY2025 Earnings

Tourmaline Bio, Inc. (NASDAQ:TRML) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Tourmaline Bio in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer expects that the company will post earnings of ($3.48) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $25.00 price target on the stock. The consensus estimate for Tourmaline Bio’s current full-year earnings is ($2.99) per share.

Tourmaline Bio (NASDAQ:TRML) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.06.

Several other analysts also recently weighed in on TRML. Guggenheim reiterated a “buy” rating on shares of Tourmaline Bio in a research report on Wednesday, December 11th. HC Wainwright reissued a “buy” rating and set a $49.00 price target on shares of Tourmaline Bio in a research report on Wednesday, December 11th. Finally, BMO Capital Markets initiated coverage on shares of Tourmaline Bio in a research report on Friday, December 6th. They issued an “outperform” rating and a $50.00 price objective on the stock. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $54.00.

Tourmaline Bio Stock Performance

Shares of TRML stock opened at $17.88 on Wednesday. The business has a 50-day moving average of $22.18 and a 200 day moving average of $21.02. Tourmaline Bio has a 1-year low of $12.12 and a 1-year high of $48.31.

Hedge Funds Weigh In On Tourmaline Bio

Several hedge funds and other institutional investors have recently modified their holdings of TRML. Brooklyn Investment Group purchased a new position in shares of Tourmaline Bio during the 4th quarter worth approximately $32,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Tourmaline Bio by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 4,932 shares of the company’s stock valued at $127,000 after buying an additional 1,920 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new stake in shares of Tourmaline Bio in the 3rd quarter worth about $226,000. Quest Partners LLC increased its stake in shares of Tourmaline Bio by 145.4% in the 3rd quarter. Quest Partners LLC now owns 9,381 shares of the company’s stock worth $241,000 after acquiring an additional 5,559 shares in the last quarter. Finally, MetLife Investment Management LLC bought a new stake in Tourmaline Bio during the third quarter worth about $357,000. Hedge funds and other institutional investors own 91.89% of the company’s stock.

About Tourmaline Bio

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.